[
  {
    "ts": null,
    "headline": "Metastatic Hormone Refractory Prostate Cancer Pipeline Market Research Report 2025 | In-depth Analysis of 180+ Companies and Over 200 Drugs in Development",
    "summary": "The report details drug profiles and phases, highlighting key players like Lantheus, Merck, and Pfizer, with a focus on novel therapeutic strategies and ongoing research.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025\" has been added to ResearchAndMarkets.com's offering. The \"Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025\" report offers an in-depth analysis of over 180 companies and 200 pipeline drugs i",
    "url": "https://finnhub.io/api/news?id=7452b499d0c3719687d1903078042bd19778b4caf6c422c2fe49c10668049685",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753454400,
      "headline": "Metastatic Hormone Refractory Prostate Cancer Pipeline Market Research Report 2025 | In-depth Analysis of 180+ Companies and Over 200 Drugs in Development",
      "id": 136088617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The report details drug profiles and phases, highlighting key players like Lantheus, Merck, and Pfizer, with a focus on novel therapeutic strategies and ongoing research.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025\" has been added to ResearchAndMarkets.com's offering. The \"Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025\" report offers an in-depth analysis of over 180 companies and 200 pipeline drugs i",
      "url": "https://finnhub.io/api/news?id=7452b499d0c3719687d1903078042bd19778b4caf6c422c2fe49c10668049685"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=e3252b44a1a5535061e1789040baef8cf95b5b6e02afd7d3bc98e7f08c72436e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753448405,
      "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 136088690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=e3252b44a1a5535061e1789040baef8cf95b5b6e02afd7d3bc98e7f08c72436e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and 3SBio conclude licensing deal for SSGJ-707",
    "summary": "SSGJ-707 is a bispecific antibody that targets PD-1 and VEGF and was developed using 3SBio’s CLF2 platform.",
    "url": "https://finnhub.io/api/news?id=f7e751b2cd268e7c350819e59e02eb5af83412ae36b52bf714e7b8e26858e350",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753444786,
      "headline": "Pfizer and 3SBio conclude licensing deal for SSGJ-707",
      "id": 136088691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SSGJ-707 is a bispecific antibody that targets PD-1 and VEGF and was developed using 3SBio’s CLF2 platform.",
      "url": "https://finnhub.io/api/news?id=f7e751b2cd268e7c350819e59e02eb5af83412ae36b52bf714e7b8e26858e350"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Comeback Is Underway",
    "summary": "Pfizer's Comeback Is Underway",
    "url": "https://finnhub.io/api/news?id=c470c7e91299396161f5b26411db6886d0bbc526c8005e4929f154db68848d32",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753440463,
      "headline": "Pfizer's Comeback Is Underway",
      "id": 136087961,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c470c7e91299396161f5b26411db6886d0bbc526c8005e4929f154db68848d32"
    }
  },
  {
    "ts": null,
    "headline": "16 Ideal 'Safer' Dividend Dogs To Buy From 70 July Graham Value All-Stars (GVAS)",
    "summary": "Discover top dividend stocks with the Graham All-Star Value (GASV) strategy.",
    "url": "https://finnhub.io/api/news?id=d9d96cf36545d8f62b9eabe32ffe7fecf985f5e829180b125befa6b353acdd22",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753438877,
      "headline": "16 Ideal 'Safer' Dividend Dogs To Buy From 70 July Graham Value All-Stars (GVAS)",
      "id": 136087899,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1138851310/image_1138851310.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover top dividend stocks with the Graham All-Star Value (GASV) strategy.",
      "url": "https://finnhub.io/api/news?id=d9d96cf36545d8f62b9eabe32ffe7fecf985f5e829180b125befa6b353acdd22"
    }
  },
  {
    "ts": null,
    "headline": "Post-Operative Nausea and Vomiting Market Report 2025: Surge in Surgical Procedures Fuels $2.97 Billion Growth in PONV Market by 2029",
    "summary": "Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in antiemetic therapies, personalized medicine, and digital health technologies. Key players include Pfizer, Merck, and Novartis. North America leads, but Asia-Pacific grows fastest. Post-Operative Nausea and Vomiting Market Post-Operative Nausea and Vomiting Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Post-Operative Nausea and Vomiting Market Report 2025\" report has be",
    "url": "https://finnhub.io/api/news?id=5df47ee56a56a6522a21a487dd2e7cf6da6a4423dca6fd0652f5d6b84ee9651c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753430580,
      "headline": "Post-Operative Nausea and Vomiting Market Report 2025: Surge in Surgical Procedures Fuels $2.97 Billion Growth in PONV Market by 2029",
      "id": 136084961,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in antiemetic therapies, personalized medicine, and digital health technologies. Key players include Pfizer, Merck, and Novartis. North America leads, but Asia-Pacific grows fastest. Post-Operative Nausea and Vomiting Market Post-Operative Nausea and Vomiting Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Post-Operative Nausea and Vomiting Market Report 2025\" report has be",
      "url": "https://finnhub.io/api/news?id=5df47ee56a56a6522a21a487dd2e7cf6da6a4423dca6fd0652f5d6b84ee9651c"
    }
  },
  {
    "ts": null,
    "headline": "GM Is Loading Up on Its Own Shares. Investors Should Follow Suit.",
    "summary": "General Motors  is too darn cheap—and the company has a solution to that problem investors should take note of.  Between its earnings and President Donald Trump’s trade deal with Japan, it was a wild week for GM.  Then shares jumped 8.7% on Wednesday, despite Trump announcing a trade deal with Japan that lowered import tariffs on cars from that nation to 15% from 25%.",
    "url": "https://finnhub.io/api/news?id=4643a4b27d26ed29a6436dc70ae3ec212cf0cd99330174224d5eb6f1cf726917",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753426800,
      "headline": "GM Is Loading Up on Its Own Shares. Investors Should Follow Suit.",
      "id": 136085090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "General Motors  is too darn cheap—and the company has a solution to that problem investors should take note of.  Between its earnings and President Donald Trump’s trade deal with Japan, it was a wild week for GM.  Then shares jumped 8.7% on Wednesday, despite Trump announcing a trade deal with Japan that lowered import tariffs on cars from that nation to 15% from 25%.",
      "url": "https://finnhub.io/api/news?id=4643a4b27d26ed29a6436dc70ae3ec212cf0cd99330174224d5eb6f1cf726917"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, BioNTech Get CHMP Backing for Updated Covid-19 Vaccine",
    "summary": "Pfizer, BioNTech Get CHMP Backing for Updated Covid-19 Vaccine",
    "url": "https://finnhub.io/api/news?id=d8b113a498abca36b574cf62e6f339853755c37648849bcfe28179f448388eaa",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753425000,
      "headline": "Pfizer, BioNTech Get CHMP Backing for Updated Covid-19 Vaccine",
      "id": 136135769,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer, BioNTech Get CHMP Backing for Updated Covid-19 Vaccine",
      "url": "https://finnhub.io/api/news?id=d8b113a498abca36b574cf62e6f339853755c37648849bcfe28179f448388eaa"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union",
    "summary": "Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulationsUpon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and olderTo date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, whic",
    "url": "https://finnhub.io/api/news?id=1fa969c0bbd489b2506fd7655199d73f549e799e70b50ea90d6c870e0cb6c2c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753425000,
      "headline": "Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union",
      "id": 136085091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulationsUpon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and olderTo date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, whic",
      "url": "https://finnhub.io/api/news?id=1fa969c0bbd489b2506fd7655199d73f549e799e70b50ea90d6c870e0cb6c2c7"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis (ZTS): Buy, Sell, or Hold Post Q1 Earnings?",
    "summary": "Over the last six months, Zoetis’s shares have sunk to $153.39, producing a disappointing 11.4% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the situation.",
    "url": "https://finnhub.io/api/news?id=1954d1ed6512270dde7de662eb27562fcf469996146f9927d28fa3e7ff2ce568",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753416069,
      "headline": "Zoetis (ZTS): Buy, Sell, or Hold Post Q1 Earnings?",
      "id": 136088692,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Over the last six months, Zoetis’s shares have sunk to $153.39, producing a disappointing 11.4% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the situation.",
      "url": "https://finnhub.io/api/news?id=1954d1ed6512270dde7de662eb27562fcf469996146f9927d28fa3e7ff2ce568"
    }
  },
  {
    "ts": null,
    "headline": "Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy",
    "summary": "BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a $66 price target, spotlighting the promising launch of Attruby for treating ATTR-CM. Citing its growing use as a first-line therapy due to […]",
    "url": "https://finnhub.io/api/news?id=a2aa5620ff2545f80533bb46e57fe5a9e41b931b9a54732db93e684c0e946615",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753415274,
      "headline": "Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy",
      "id": 136085092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a $66 price target, spotlighting the promising launch of Attruby for treating ATTR-CM. Citing its growing use as a first-line therapy due to […]",
      "url": "https://finnhub.io/api/news?id=a2aa5620ff2545f80533bb46e57fe5a9e41b931b9a54732db93e684c0e946615"
    }
  }
]